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4I am delighted to welcome this new report from
the NACD on the potential usefulness of
Lofexidine as a treatment option in the
management of opiate dependency.
Through its three-year research work programme,
the NACD is seeking to address gaps in our
knowledge of drug misuse in an Irish context.
The results of this work, of which this report is 
an important part, will significantly increase the
amount of available research, which will facilitate
greater evidence-based policy making in this
difficult and complex area. 
Drug misuse, particularly opiate misuse, remains
one of the major social problems facing Irish
society today. The Government will continue 
to work in partnership with communities most
affected by the problem. Implementing the 100
actions in the National Drugs Strategy 2001-2008
and initiatives such as the Local and Regional
Drugs Task Forces remains a priority for
Government.
The Strategy aims to broaden the range of
treatment approaches available to drug misusers.
In this context, it aims to have in place in each
Health Board area a range of treatment and
rehabilitation options as part of a planned
programme of progression for each drug misuser.
The study suggests that Lofexidine may be useful
as an additional treatment for managed opiate
withdrawal. 
I welcome the report, therefore, and hope that 
it will help to aid the overall treatment of opiate
users in this country.
Noel Ahern T.D.
Minister of State with responsibility for the
National Drug Strategy
Minister of State’s Foreword
5As part of its efforts to advise Government on 
the treatment and rehabilitation of problem drug
users, the NACD has initiated several studies of
different treatment approaches. Some of these
approaches involve the use of medication to
assist in achieving abstinence while some do not.
Similarly some treatments involve substitute or
maintenance prescribing while other treatment
modalities are strictly drug and medication-free.
The NACD monitors developments in a whole
range of treatment approaches and, as such,
became aware of increased interest in the 
use of non-opiate based approaches to the
management of withdrawal from opiates such 
as heroin and methadone.
It is our hope that this overview of the use of
Lofexidine will provide useful and timely
information to all those involved in service planning
and delivery in the addictions area whether at
national, regional or local level. Not surprisingly, 
the challenge will be to establish which clients
presenting for treatment are likely to benefit from
this particular medication. We are confident that
the experience of using this aid to withdrawal, 
so excellently and professionally catalogued by 
Dr. Mary Teeling and her colleagues, will be of
enormous benefit to those wishing to intervene
with clients seeking to explore the drug-free
treatment options available to them. 
Dr. Desmond Corrigan
Chairperson
NACD
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Glossary
8Opiate dependency continues to be a cause 
of morbidity and premature mortality among 
the inhabitants of the EU. Although many
treatment modalities have been used, 
the pharmacotherapeutic approach, using
methadone maintenance therapy, has proved
most beneficial to date and is the mainstay 
of treatment in the Irish setting.
A systematic review was undertaken in order to
evaluate the potential usefulness of lofexidine as
a treatment option in the management of opiate
dependency. All available data were retrieved by
means of a comprehensive search of the published
literature. Contact was made with experts in
Ireland to evaluate the practical issues associated
with use of lofexidine in a clinical setting.
Evaluation of clinical trials data for lofexidine
showed that it appeared to be at least as
effective as clonidine and reducing doses 
of methadone, the other treatment regimens
currently used in the treatment of opiate
withdrawal. It was not possible to define the
optimal dosage regimen for this indication,
because of the lack of data from controlled 
trials, but in general incremental dosing was 
used reaching a maximum of around 2.2mg/day
by day 3-4, with gradual tapering of dose until
zero by day 10.
Evaluation of its use in clinical practice showed
that it was considered as effective as clonidine 
for managed withdrawal but had a better safety
profile (i.e. less hypotension). Experts have
suggested that lofexidine detoxification requires
intensive input from all members of the drug
treatment team and should be followed up by
further treatment to prevent relapse. Although
there were insufficient data to evaluate its use in
specific subgroups, most workers have suggested
that lofexidine is more effective in younger
patients and those who have a shorter, less
entrenched history of opiate use.
The review suggests that lofexidine may be
useful as an additional treatment for managed
opiate withdrawal. 
Executive Summary
9Problem drug use, defined as injecting drug 
use of long-duration/regular use of opiates,
cocaine and/or amphetamines, continues to be 
a problem throughout the European Union (EU).
A recent capture recapture study of the
prevalence of opiate use in Ireland 2000-2001
(Kelly et al, 2003) showed an overall prevalence 
of opiate use of 5.6/1,000 population. Males aged
25-34 years had a higher national prevalence (13.7
and 14.7/1,000 pop for 2000 and 2001) compared
with the remaining males and females of all ages.
The current National Drugs Strategy 2001-2008,
(entitled Building on Experience) which was
approved by the Irish Government in April 2001,
contains 4 “pillars” for tackling the drugs issue,
namely supply reduction, prevention (including
education and awareness), treatment (including
rehabilitation and risk reduction) and research. 
Methadone maintenance is still the major form 
of treatment in Ireland and this is provided to
persons who fulfil specific criteria of admission
(Sinclair et al, 2001). Buprenorphine has been
used as a maintenance treatment in some EU
countries since 1996 and was recently authorised
for such use by the Irish Medicines Board in
Ireland. The National Advisory Committee on
Drugs (NACD) previously commissioned a review
of the usefulness of buprenorphine (Teeling et al,
2002) and this showed that buprenorphine could
be considered a useful treatment option in the
management of opiate dependence in Ireland
with an acceptable safety profile. It is reported
that the Pharmaceutical Society of Ireland has
proposed that the use of non-opioid alternatives
to methadone (such as lofexidine) should be
considered for use in the management of opioid
dependence in the future (Sinclair et al, 2001).
Managed withdrawal, using a variety of medications
including methadone, buprenorphine, as well 
as other (non-opioid) agents, has been evaluated
infrequently as a type of treatment intervention 
in opiate dependency. Following on from 
the buprenorphine review, the NACD has
commissioned this review of lofexidine, a 
non-opioid agent, which has been used in 
the management of opiate withdrawal in the UK
for several years. The review was commissioned
to evaluate the potential usefulness of lofexidine
in the overall management of opiate
dependence syndrome in the Irish setting.
Introduction
Chapter 1
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The aim of this review was to evaluate the
usefulness of lofexidine as a treatment option 
in the management of Opiate Dependence
Syndrome.
The objectives of the review were to:
1. Retrieve all published information on the use
of lofexidine in the management of opiate
dependency, in particular, its use in managed
opiate withdrawal. 
2. Undertake a systematic review of the clinical
studies retrieved, including a formal meta
analysis if the data permitted.
3. Evaluate the practicalities of use of lofexidine
in different treatment settings (inpatient clinics
and outpatient clinics/primary care) including
an assessment of safety issues such as need
for regular medical supervision and patient
acceptability.
Aims and Objectives of the Review
Chapter 2
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Primary and review articles, abstracts and other
published information on lofexidine were
identified using the following sources –
 Medline, Pharmline, Micromedex, Iowa Drug
Information Service, (computerised indexing
and retrieval systems)
Review journals (such as Drugs) and reference
textbooks (Martindale 32nd edition,
“Pharmacological Basis of Therapeutics”
Goodman and Gilman 10th Edition) were 
also searched for background pharmacology.
The National Documentation Centre’s electronic
library and specialist textbooks were searched 
for relevant articles and publications.
The search terms used were as follows – opiate,
opioid, lofexidine, α2-adrenergic agonist,
addiction, therapeutic, withdrawal, detoxification,
methadone and heroin. These were employed
separately and in combination with one another.
The reference lists of relevant articles and reviews
were examined for further reports.
No time limit was put on the earliest date for
acceptability of data and studies were evaluated
from 1980 onwards. The data lock point for
inclusion in the review was the 15th December,
2002. Articles that became available after that
time were taken into account if they were judged
to provide additional information, which might
influence the outcome of the review. Once
identified, all papers were evaluated for
relevance to the review and were included 
in the assessment if considered relevant.
Data from randomised controlled clinical 
trials with lofexidine were pooled in order 
to determine whether it was appropriate 
to undertake a meta analysis to compare 
the efficacy of lofexidine with methadone 
and clonidine in the management of opiate
withdrawal. A meta analysis is a statistical
technique for combining the results of
independent studies, to present an objective 
and quantitative measure of the effectiveness of 
an intervention. It reduces the chances of Type II
errors by pooling the data across several smaller
studies and therefore increases the confidence
with which the efficacy of an intervention can 
be assessed (Sutton et al, 1999; Chalmers and
Altman, 1995).
The data on lofexidine were systematically
reviewed to determine the optimal dosing
regimen and to see if it might be more effective
for certain sub-groups of patients. Safety was
assessed using published data on clinical usage.
Finally, in order to identify the practicalities of
use, information on use of lofexidine in clinical
practice was identified from the published
literature. Where possible, Irish healthcare
professionals who had experience of use 
of lofexidine in the management of opioid
dependence were identified and contacted 
for further specific data on the advantages and
disadvantages of such usage in clinical practice. 
Research Methodology of the Review
Chapter 3
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Lofexidine
4.1 Introduction
Many of the features of opiate withdrawal (e.g.
sweating, hyperactivity, restlessness, irritability)
are thought to be due to a hyperarousal of the
locus coeruleus (Guthrie, 1990). The locus
coeruleus possesses inhibitory α2-adrenergic
receptors as well as opioid receptors, therefore
an α2-adrenoreceptor agonist should be
effective in treating withdrawal. Clonidine, 
a central and peripheral α2-adrenoreceptor
agonist has been shown to ameliorate these
opiate withdrawal symptoms but its risk of
hypotension has made it unsuitable for
outpatient use (Cox and Alcorn, 1995).
4.2 Pharmacology
Lofexidine is a structural analogue of clonidine. 
It is an imidazoline with a high affinity for α2-
adrenergic receptor subtypes (SPC, 2003). This
makes it less likely to cause hypotension than
non-selective α2-adrenergic agonists, while
retaining potent in-vitro noradrenergic antagonist
activity (Cox and Alcorn, 1995). Lofexidine has
been reported to reduce withdrawal body shakes
induced by discontinuation of chronic morphine
infusion in rats, in a dose dependent manner. 
The activity of lofexidine was not prevented 
by naloxone (Shearman et al, 1980).
Although lofexidine has been used as a
treatment for managed opioid withdrawal for
many years, the number of published controlled
studies remains small. An early clinical study 
with lofexidine (Gold et al, 1981) in chronic
methadone users showed a significant reduction
in opiate withdrawal symptoms from 2 hours after
a dose of lofexidine of 0.2mg in 12/15 subjects.
Subsequent studies have shown that lofexidine
resolves withdrawal symptoms earlier than
methadone.
Full details of published studies together with
information of its effectiveness in clinical practice
are found in Chapter 5.
4.3 Pharmacokinetics
Following oral administration lofexidine is rapidly
and almost completely absorbed. Studies using
14C -lofexidine hydrochloride in healthy male
volunteers indicate an oral bioavailability > 90%
(lofexidine company expert report). Peak plasma
concentrations are obtained some 3 hours (range
2 to 5 hours) following oral administration.
Plasma protein binding is estimated at 80 – 90%
and is unlikely to be clinically relevant from 
the drug interaction standpoint. The terminal
elimination half-life is approximately 11 hours
following oral dosing (1.2mg and 2.0mg) 
in healthy volunteers. This indicates that 
steady state plasma concentrations will be
achieved after 55 hours. Studies indicate linear
pharmacokinetics over the dose range 0.4mg b.d.
to 1.2 mg b.d. Detailed pharmacokinetics data
are limited, however 14C - lofexidine studies 
in healthy male volunteers indicate significant
hepatic metabolism with four metabolites
detected. The glucuronide metabolites
accounted for 50% of those identified.
Approximately 10% of the drug appears
unchanged in the urine. 
From the drug interaction aspect, caution 
should be used when combining lofexidine 
with other medications that undergo significant
glucuronidation. Such compounds include
analgesics (paracetamol, ketorolac, ketoprofen,
naproxen), anticonvulsants (lamotrigine, valproic
acid), anti-infectives (atoraquone, zidovudine),
anti-hypertensive agents (labetalol), lipid lowering
drugs (gemfibrozil), and the sedative/hypnotics
(oxazepam, lorazepam, temazepam, propofol). 
Pharmacodynamic interactions may also occur
when lofexidine is given in combination with
alcohol, sedatives, anti-hypertensive agents 
and tricyclic antidepressants. Particular care
should be taken where pharmacokinetic and
pharmacodynamic interactions may occur 
e.g. concurrent use of alcohol, sedatives 
and labetalol. There are few data available on
formal drug interaction studies with lofexidine.
Pharmacology
Chapter 4
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4.4 Summary
Lofexidine is an orally active α2-adrenergic
agonist which shows less anti-hypertensive
activity than clonidine. It undergoes hepatic
metabolism and may interact with other
medications that undergo significant
glucuronidation. Caution should be exercised 
in situations where pharmacokinetic and
pharmacodynamic interactions may occur 
e.g. concomitant use of alcohol, sedatives 
and labetalol.
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5.1 Introduction
The availability of managed withdrawal 
is essential for the provision of an effective
treatment system for opiate dependence
(Gowing et al, 2001). It may be used either 
as a treatment entity in its own right, as a first
step for other forms of treatment or at the end 
of maintenance treatment (Teeling et al, 2002).
5.2 Clinical Studies with Lofexidine
It has been known for some time that α2-adrenergic
agonists are effective in managing the symptoms 
of opioid withdrawal (see chapter 4). Although
lofexidine has been used for the management of
opioid withdrawal for several years, most of the
published studies evaluating the use of α2-adrenergic
agonists have used clonidine. The Drugs and Alcohol
Group of the Cochrane Collaboration have
undertaken a series of systematic reviews evaluating
the different modalities of treatment in the
management of opioid withdrawal. These provide
the biggest body of data which examines the role 
of lofexidine in this treatment setting.
5.2.1 Systematic Reviews
1) “α2-adrenergic agonists for 
the management of opioid
withdrawal” (Cochrane Library)
This review, undertaken by Gowing et al (2002a),
provides a systematic review of α2-adrenergic
agonists in the management of opioid withdrawal.
The focus of the review was to evaluate the
effectiveness of these agents in this indication
relative to other forms of treatment, placebo 
and each other. As with all Cochrane reviews 
an extensive search of electronic databases 
with subsequent retrieval of all relevant references
was undertaken. Although the time limits on 
data collection were not specified, the retrieval
identified papers from 1978-2000 and the
systematic review included papers from 1981-1999.
A total of 68 studies were identified in the data
retrieval process of which 24 were judged to fulfil
the criteria for inclusion in the systematic review.
Grounds for exclusion included no concurrent
comparison treatment, insufficient data on either
the treatment protocol, participant characteristics
or study outcomes and variable treatment
protocols.
Only 6 of the included studies evaluated the 
use of lofexidine (n = 200 subjects). Table 5.1
summarises the included studies. There was 
no consistency between the studies in terms 
of dosage regimens, duration of treatment or
comparator used. In general, initial doses ranged
from 0.6 – 1.8mg/day administered in 2 or 3
doses. All studies used incremental dosing up 
to a maximum of 2mg/day, usually achieved by
the fifth day. Doses were subsequently tapered
off to zero by day 10-18 (where stated). One
study (Bearn et al, 1998) used an accelerated
detoxification regimen which involved 1.8mg
lofexidine/day on day 1, followed by 2mg for 
3 days and then 1.2mg on day 5, all administered
in divided doses. Only one study was in an
“outpatient” setting - home treatment with
regular house visits. Four were inpatient studies
and the sixth study was undertaken in prison. 
This latter study undertaken by Howells et al, 
was unpublished at the time of the review but
has since been published (Howells et al, 2002).
The results were presented as follows 1)
withdrawal syndrome 2) duration of treatment 3)
completion of withdrawal and 4) nature and
incidence of adverse effects. It was not possible
to undertake definitive quantitative meta-analysis
on these criteria because of the heterogeneity 
of the protocols and conduct of the studies.
Moreover, the reviewers had hoped to evaluate
the effects of concurrent use of alcohol and 
other drugs via subgroup analysis but there 
were insufficient data to report on this.
Withdrawal Syndrome
The studies appeared to show that withdrawal
signs and symptoms emerged more quickly 
in participants treated with lofexidine when
compared with tapering doses of methadone.
The main withdrawal symptoms reported were
insomnia, drowsiness, anxiety, irritability, lethargy,
aches/pains (including bone pain) and feeling of
cold. Howells et al (2002) suggested that 
aches and pains and feeling cold were greater
Review of Clinical Usage with Lofexidine
Chapter 5
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problems for the lofexidine group whereas
drowsiness scores were higher in the methadone
treated group. Kahn (1997) showed that bone
pain and insomnia were particular problems for
both lofexidine and clonidine – treated patients.
Howells et al (2002) showed that withdrawal
scores were consistently 5-10% higher in the
lofexidine group compared with methadone.
However, this study was conducted in a prison
setting, with study entry occurring after 24-48
hours in custody and therefore the interval
between the last opiate use and study entry, 
is uncertain. Therefore, the results may be
confounded by time since last opiate use.
No significant difference in efficacy between
clonidine and lofexidine was reported in any 
of the studies. Peak withdrawal scores were
reported to occur on or about the second 
day of treatment (later if the participant 
was withdrawing from methadone).
It was noted by the reviewers that none of the
treatments evaluated appeared to fully suppress
the aches and pains, sleep disturbances, 
anergy, chills or anxiety associated with 
withdrawal.
Duration of Treatment
There was a marked difference in the duration 
of treatment between regimens used as reducing
doses of methadone needed a much longer
period of detoxification (minimum of 20 days)
compared with the use of an α2-adrenergic
agonist (10 days usually). Therefore, it was
difficult to compare apparent differences in
absolute duration of treatment for the different
treatment groups. It would appear that those
treated with lofexidine were less likely to be
retained in treatment for the scheduled period 
of treatment compared with tapering methadone
treatment. However, this finding is subject to
huge confounding which makes comparisons
difficult to interpret. There was no difference in
retention rates between lofexidine and clonidine.
Completion of Withdrawal
Definitive data on completion of withdrawal were
not reported in all studies. Moreover, some of the
data (Howells et al, 2002) had to be disregarded
as 12 of the 23 participants who withdrew early
did so for administrative rather than treatment
related reasons. From the data available it would
appear that the completion rates were similar for
lofexidine and clonidine and similar (or slightly
less) for lofexidine when compared with reducing
doses of methadone. It was not possible to say if
use of lofexidine was better in heroin withdrawal
or methadone maintenance withdrawal.
Nature and Incidence of Side Effects
Hypotension was not reported to be a 
major problem with use of lofexidine when
compared with reducing doses of methadone.
No participants were withdrawn because of
hypotension and only small numbers of subjects
needed a reduction in dose. Of interest is the
fact that the study from Bearn and workers (1998)
which used two different lofexidine treatment
regimens, (see Table 5.1) reported no significant
difference in mean blood pressure between the
two lofexidine groups. 
Clonidine comparative studies reported
consistently more hypotension with clonidine
compared with lofexidine, resulting in
significantly more omissions of, or reductions 
in, dose for the clonidine groups.
There is very little information on other adverse
effects of treatment, as most of the studies
focused on the possibility of hypotension. There
are no data to suggest that the adverse effect
profile of lofexidine is worse compared with
clonidine or reducing doses of methadone 
for non-hypotension events.
Conclusions
The reviewers noted that α2-adrenergic 
agonists could be used for the management of
withdrawal. In comparison with reducing doses of
methadone, such use was associated with shorter
duration of treatment and similar or slightly lower
rates of completion of withdrawal. The signs and
symptoms occurred earlier and also resolved at
an earlier stage with α2-adrenergic agonists.
Lofexidine appeared to cause less hypotension
than clonidine. Because of this finding and the
fact that clonidine and lofexidine are equally
effective, the reviewers recommend that
lofexidine should be the preferred option,
particularly for withdrawal in an outpatient
setting, if an α2-adrenergic agonist is to be used.
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Table 5.1
Lofexidine Studies included in Cochrane review “α2-adrenergic agonists for the management of opioid withdrawal” 
(Gowing et al, 2002a)
Study Type Numbers Doses ** Comparator Results
Bearn RCT 42 Lofex; Lofex: 0.6mg/d increasing Meth: variable start “Broadly equivalent” 
et al, 1996 db 44 Meth; by 0.4mg/d until day 4; dose ↓ x10d but more w/d 
on heroin max dose of 2mg/day symptoms with lofex
+/- meth x 3d + tapering x3d early in treatment.
No BP problems.
Bearn RCT 22 Lofex (1); (1) Lofex 0.6mg/d ↑ to 2mg/d Meth variable start Overall similar
et al, 1998 20 Lofex (2); tapered to zero by d10 dose ↓ x 10d rates of completion. 
19 Meth; (2) Lofex 1.6mg/1d; 1mg/x3d; (1) Lofex achieved 
on heroin 0.6mg x 1d earlier detoxification. 
+/- meth No BP problems.
* (All subjects
stabilised on
meth prior to
w/d treatment)
Carnwarth RCT 26 Lofex; Lofex 0.6mg/d ↑ to 1.6mg/d Clon 0.2mg/d ↑ to 0.8mg/d 17/26 +12/24
et al, 1998 db 24 Clon; then ↓ over 3d to zero at d12 then ↓ x 3d to zero at d12 completed treatment 
(+10 left trial (ns). More hypotension 
before treatment) with Clon.
on heroin +/ meth
Howells RCT 32 Lofex; Lofex 0.6mg/d ↑ X 0.4mg/d Meth 30mg x 1d ↓ x 5mg No significant 
et al, 2002 db 36 Meth; to 2mg/d x3 ↓ 0.4mg/d x3 every second day to zero difference in
unpublished (8 who were (10 days) by d10 symptoms.
at time of randomised (but see text)
Cochrane not included);
review “opiate-
dependent”
non-specific
Kahn RCT 14 Lofex; Lofex 0.4mg/d ↑ to 1.8mg/d Clon 0.2mg/d ↑ to 0.9mg/d No significant
et al 1997 db 14 Clon; if necessary. if necessary. difference in
all stabilised Tapered to zero by d18 Tapered to zero by d18 completion
on meth rates but lofex
caused less 
hypotension.
Lin RCT 40 Lofex; Lofex 0.8mg x 1d ↑ to Clon 0.3mg x 1d ↑ to No significant 
et al, 1997 db 40 Clon; max of 1.6mg/x2d max of 0.8mg x 2d difference in 
on heroin then tapered to zero then tapered to zero completion
rates but lofex
caused less 
hypotension.
Legend
** Lofexidine usually administered in divided daily doses.
Lofex = Lofexidine db = double blind
Clon = Clonidine w/d = withdrawal
Meth = Methadone BP = blood pressure
RCT = Randomised controlled trial
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2) “Methadone at tapered doses 
for the management of opioid
withdrawal” (Cochrane Library) 
This review (Amato et al, 2002) compared 
the usefulness of reducing doses of methadone
with α2-adrenergic agonists, other opioids 
and placebo in the management of opiate
withdrawal. Of 10 studies, which compared
reducing doses of methadone with α2-adrenergic
agonist treatment, only 2 involved use of
lofexidine (n = 42 lofexidine-treated subjects 
in each study). Details of these studies are given
in table 5.1 (Bearn et al, 1996; Bearn et al, 1998).
The review showed that lofexidine was
comparable with methadone in terms of efficacy
and safety. The reviewers commented on the
wide variability of the data, which precluded
quantitative meta analysis. 
3) “Effectiveness of short-term use of
buprenorphine in the management
of  opioid withdrawal” (Cochrane
Library)
A full report of this review (Gowing et al, 2001) 
is contained elsewhere (Teeling et al, 2002). It is
interesting to note that this review contains no
comparison between lofexidine and buprenorphine,
highlighting the lack of published data with
lofexidine. A recently published open label 
study from the UK (White et al, 2001) compared
the efficacy of lofexidine with buprenorphine 
in the management of withdrawal in 69 opiate-
dependent subjects. A maximum of lofexidine
2.4mg/day using variable dosage regimens 
was used, compared with a maximum daily dose
of 8mg buprenorphine. The treatment period
allowable for detoxification was up to one month.
Results showed that subjects were more likely 
to experience a severe withdrawal syndrome and
less likely to complete treatment with lofexidine
compared with buprenorphine. This study has
many methodological flaws but is the only
published comparative study evaluating lofexidine
and buprenorphine in this treatment setting.
4) “Lofexidine for Detoxification:
Review of recent randomised 
and open controlled trials” 
(Strang et al, 1999)
All of the studies in this review were included in
the Cochrane review outlined above (Gowing et
al, 2002a) and the conclusions drawn were similar.
Lofexidine was found to have similar efficacy as
clonidine and methadone regimens, but without
the hypotensive problems of clonidine. These
reviewers made the point that lofexidine may 
be particularly useful for managed withdrawal 
in situations where there is a problem using
reducing doses of methadone, such as in the
prison environment where there may be concerns
about abuse or diversion, or in situations where
methadone may not be available or acceptable
for use by the treating clinician. 
5.2.2 Other Studies with Lofexidine
Several published studies including small
numbers of patients have evaluated the use 
of lofexidine in the management of withdrawal 
in an outpatient setting. Brown et al (1998)
reported successful detoxification in 11/28 (39%)
individuals, half of whom were taking heroin and
the remainder were on methadone maintenance.
Lofexidine was administered on a sliding scale for
14 days at a maximum of 1.6mg/day. The subjects
were managed at home by community psychiatric
nurses/community workers. The opiate was
stopped 48 hours after initiation of lofexidine.
Lofexidine was more likely to be successful in
methadone-maintained subjects and those who
had been taking heroin for less than one year. 
As the maximum dose of lofexidine used was
1.6mg/day, the authors suggested that this 
dose may have been insufficient for heroin
detoxification.
In a study by Eveleigh (1995), detoxification 
was undertaken with lofexidine in an outpatient
setting in 6 subjects, maintained on methadone.
A maximum dose of lofexidine 1.6mg/day was
allowed and the treatment duration was 16 days.
Lofexidine was administered in incremental 
doses reaching maximum dosage from days 5-12
with subsequent tapering of dose. All subjects
completed the withdrawal treatment satisfactorily
although 4 had relapsed by 2 months (2 at 2 weeks).
The remaining 2 remained drug-free at 6 months.
Subjects complained of sleeplessness,
restlessness and bone aches during their 
period of withdrawal. The investigator noted 
that all subjects who relapsed stated that they
had returned to drugs because they could 
not cope with their thoughts and/or emotions, 
thus highlighting the need to continue treatment
(opiate antagonist and counselling) after the
initial period of withdrawal has been successfully
completed.
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Washton and workers (1983) evaluated the use 
of lofexidine in 30 opiate dependent outpatients
who were receiving substitution therapy with
either methadone (10-45mg /day) or levo-alpha
acetyl-methadol (LAAM) at doses of 28-43mg 
per week. Incremental lofexidine doses up to
2mg/day were used and success was defined as
remaining opiate – free for at least 10 days after
the last dose of methadone (14 days after LAAM).
Subjects who had not successfully completed
detoxification by 21 days were offered alternative
treatment. Results showed 21/30 subjects (70%)
completed detoxification. Only 2 of the 9 
non-completers attributed their failure to
unacceptable withdrawal symptoms. The
remainder (n = 7) cited “opiate craving” or 
“not ready to detoxify” as reasons for returning
to opiate use. Of interest, no relationship was
found between the level of maintenance therapy
prior to lofexidine and degree or severity of
withdrawal symptoms. No hypotension was 
noted even at the maximum dose of 2mg
lofexidine/day. However, this study did note 
that the withdrawal symptoms of insomnia 
and lethargy were not alleviated to any extent 
by lofexidine. Moreover, it also highlighted 
the need to ensure that lofexidine is used as part
of a treatment programme (e.g. as a short-term
treatment used to switch patients from opiate
dependence to opioid antagonist therapy).
Summary
Lofexidine has been shown to be an effective
treatment in the management of opioid
withdrawal. It has been shown to be as effective
as clonidine and reducing doses of methadone
and has a better safety profile than clonidine 
in terms of hypotension. It does not appear 
to eliminate withdrawal symptoms completely
(especially insomnia and lethargy) and ancillary
treatments are usually necessary. Dosage
regimens have varied between studies, but 
in general doses, should be titrated to the
individual’s symptoms. Doses up to a maximum
of 2.2mg/day have been administered in divided
doses, without significant hypotension. Treatment
has generally lasted for approximately ten days
although this has been extended in some
subjects according to need. An accelerated
regimen of five days has been shown to be as
effective as the standard regimen in one study
but this involved very small numbers (n = 22). 
α2-adrenergic agonists such as lofexidine have
been judged to be particularly suited to those
who are well motivated and who seek an earlier
resolution of withdrawal symptoms. However,
investigators (Gowing et al, 2002b) have stressed
the need to use lofexidine within a treatment
programme involving follow-up opioid antagonist
treatment and counselling.
5.3 Lofexidine in Combination
with Opiate Antagonists
The opioid withdrawal syndrome is rarely 
life-threatening but it makes completion of
withdrawal without medication difficult for 
most people. In recent years, studies have 
been undertaken to investigate the value 
of an opioid antagonist in combination with
medication, including α2-adrenergic agonists, 
to ameliorate withdrawal symptoms, as a
treatment option for managed withdrawal. 
Such regimens are used to shorten the period 
of detoxification (Merrill and Marshall, 1997). 
The rationale is that a more rapid transition 
from dependence to abstinence might increase
rates of withdrawal (Gowing et al, 2002c).
Two published studies compared a lofexidine/
opioid antagonist combination with conventional
lofexidine therapy. Both of these studies were
open label in design and patients were allowed
to choose their treatment option. Treatment
regimens differed between the two studies (Table
5.2) and were administered in specialist hospital
units. Buntwal et al (2000) showed no significant
difference in terms of the numbers of patients
completing detoxification or the average length
of stay between the two treatment groups (80% 
+ 73%). It was noted that the withdrawal
symptoms were significantly less severe with the
combination whereas the adverse effect profile
was similar. However numbers were small (n = 11
per group). Bearn et al (2001) showed no overall
additional benefit with the lofexidine/naloxone
combination in terms of rates of completion of
detoxification or length of stay in treatment,
although symptom severity was less during
combination treatment. The authors postulated
that the level of opioid receptor blockade with
the treatment regimen used was inadequate 
to accelerate reversal of the dependence -
associated neuroadaptatory changes. They
suggested that the rate of antagonist occupancy
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of opiate receptors may be a critical factor in
determining the rate of resolution of opiate
withdrawal. It is important to note that this study
also involved small numbers (n = 49) and four
patients changed treatment during the study
(final numbers n = 26 for the combination; 23 
for lofexidine only).
A double-blind randomised controlled study
(Gerra et al, 2001) compared lofexidine/naloxone
(n = 20) with a clonidine/naloxone regimen (n =
20) administered in an outpatient setting, over 
3 days. All subjects were heroin dependent and
had entered an outpatient recovery programme.
All medications (including oxazepam, baclofen
and ketoprofen) were administered in outpatient
clinics for the three days of detoxification 
(Table 5.2). Patients were subsequently offered
naltrexone maintenance along with counselling
for a further three months. Results showed 
that the lofexidine-treated group suffered 
less withdrawal symptoms and mood changes
compared with clonidine, although completion
rates were similar (18 + 17 respectively).
Approximately 75% of all those completing
detoxification entered the naltrexone
maintenance programme. Clonidine caused 
a significant decrease in mean systolic blood
pressure compared to baseline but it is not clear
from the report whether this resulted in dosage
reduction in any patient. Lofexidine did not
induce any significant change in blood pressure.
Although this was undertaken in an “outpatient”
setting, participants needed close monitoring
during detoxification in a clinic and were 
closely monitored during the subsequent weeks.
However, the authors conclude that these results
suggest that lofexidine, in combination with
opioid antagonist therapy, could be considered
in an outpatient setting and future studies should
evaluate this possibility.
Conclusions
Limited data are available evaluating the
usefulness of lofexidine in combination with 
an opioid antagonist in managed opiate
withdrawal. The available studies suggest 
that the combination is at least as effective as
lofexidine alone and may also be associated 
with less severe withdrawal symptoms than
lofexidine monotherapy. It also enables the
period of detoxification to be shortened and 
this may help to improve rates of withdrawal 
and facilitate transfer to naltrexone maintenance
programmes. Further studies are needed to
determine the optimal treatment regimen. Finally,
although some workers have suggested that the
combination regimen of lofexidine and an opioid
antagonist could be useful in an outpatient
setting, more studies are needed to confirm this.
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Table 5.2
Lofexidine/Opioid Antagonist Combination Studies
Study Type Numbers Doses ** Comparator Results
Buntwal Open 11 Lofex/ Lofex 1.8mg Nalox 0.8mg 1/M W/D symptoms less 
et al, 2000 label nalox/nalt; x 1d Lofex 2mg severe in combination 
11 Lofex; 2mg x 4-5d Nalt 14mg group. No difference
on heroin 1mg x 1d Nalt dose ↑ in rates of completion
x/- meth (7days) To 50mg by d 4; of detoxification.
Lofex dose ↑ to 1.8mg by 
d3 then ↓ to zero by d5
Bearn Open (1) 30 Lofex/ (1)* Lofex 2mg x 2d; (2)* Lofex 1.8mg x 1d; No significant
et al, 2001 label Nalox Nalox 0.8mg 1/m +Lofex Lofex 2mg x 5d; difference
(2) 19 Lofex; 1.6mg/x 4; Lofex 1.2mg x 1d between
(4 switched from treatments.
(1) to (2) during * all were stabilised 
study) all had on meth x 3d prior 
poly-substance to detoxification
abuse
Gerra RCT (1) 20 Lofex/ (1) Lofex 1.2mg x 1d; (2) Clon 0.9mg on d1; Lofex more useful
et al, 2001 db nalox/nalt; Lofex 1.6mg, Nalox Clon 1.2mg, Nalox 0.4mg in treating W/D
(2) 20 Clon/ 0.4mg IV + Nalt 5mg on d2; IV + Nalt 5mg on d2; symptoms and
nalox/nalt; Lofex 1.2mg, Nalox Clon 0.9mg, Nalox 0.4mg caused less
all on heroin 0.4mg IV + Nalt 50mg on d3 IV + Nalt 50mg on d3 hypotension
than Clon.
Legend
** lofexidine and clonidine were given in divided daily doses
RCT = Randomised controlled trial Nalox = Naloxone
db = double blind Nalt = Naltrexone
Lofex = Lofexidine Clon = Clonidine
Meth = Methadone W/D = Withdrawal
}d1
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5.4 Use of Lofexidine in 
Clinical Practice
5.4.1 United Kingdom
Lofexidine is authorised in the UK to “relieve
symptoms in patients undergoing opiate
detoxification” (SPC, 2003). Since its launch 
in 1992, usage has increased steadily and one
report noted that more than 18,000 courses of
lofexidine treatment were used in the UK in 1998
and this usage was estimated to increase to more
than 21,000 in 1999 (Strang et al, 1999).
The results of a national survey on the efficacy
and safety of lofexidine were recently published
(Akhurst, 1999; Akhurst, 2000). The survey was
conducted under the guidelines for company-
sponsored safety assessment of marketed
medicines (SAAM). A total of 1,074 questionnaires
from 40 randomly chosen drug dependency units
were completed and available for evaluation. 
The data set comprised 793 males and 270
females. Approximately 43% were taking heroin,
28% methadone and 20% both. The majority had
been dependent on opiates for ≤ 5 years and
almost three quarters had either never attempted
a supervised detoxification before or had a
maximum of 2 previous attempts.
Detoxification with lofexidine was undertaken in
the community in 63% cases. The mean starting
dose used was 0.8mg/day with the majority 
of patients achieving their maximum dose by 
day 3. Most patients were titrated to a mean
maximum dose of 2.2mg/day although doses up
to 5.6mg/day were recorded. The mean duration 
of treatment was 8.9 days (range 1-33 days) with 
a mean of 10 days for those who successfully
completed treatment. Of interest, the duration 
of detoxification was significantly less for
inpatients (mean 7.9 days) compared with
outpatients (mean 9.5 days).
Information on efficacy was available on 686
detoxification episodes, of which 342 (49%) 
were rated as very successful, 261 (38%) as
moderately successful and 83 (12%) as poor.
Follow-up information was not available from 
all questionnaires but 333 patients were reported
to be opiate-free for a period ranging from 3
days to 3 years and 327 patients were known 
to have relapsed. Of interest, 221 questionnaires
recorded an improved lifestyle relating to
relationships, employment and/or health status.
Adverse events were reported in 351/1074
(32.7%) detoxification episodes of which 239 were
considered to be probably or possibly related to
treatment (according to the WHO classification).
Commonest events reported were dizziness
(8.5%) sedation (6.6%) insomnia (4%) dry mouth
(5%). Hypotension was recorded in 7.5% cases
and this resulted in discontinuation of treatment
in 16 cases and reduction in dosage in a further
47 cases. It is important to note that not all 
of the treatment units routinely monitored 
blood pressure and pulse rate, but from the data
available it was noted that if hypotension and/or
bradycardia were to occur, this usually happened
within the first few days. Moreover, no record of
hypotension, bradycardia or other adverse event
was noted in the cases where doses of lofexidine
in excess of 2.4mg/day were used.
This SAAM study involved a retrospective review
of patient files and therefore data collection was
incomplete for a number of the parameters. In
addition the adverse events recorded in the files
related primarily to symptoms as routine blood
testing which might have picked up “concealed
adverse events” (e.g. liver or renal dysfunction)
was not undertaken. However, useful information
on the general safety of lofexidine has been
made available from this survey.
The use of lofexidine in 194 patients undergoing
214 opioid detoxifications over a 24 month
period was reviewed by Sheridan et al (1999). 
All patients had been treated in the acute
assessment unit at the Maudsley Hospital (UK)
over a 24 month period (1994-1996). These
patients had a significant drug-related problem
and were resident in the catchment area of the
hospital. The group included 151 males and 
43 females with a mean age of 29.7 years 
(19-58 years), most of whom (n = 179) were
unemployed. The majority of patients were
dependent on heroin (by injection) and/or
methadone. The mean duration of dependence
was 95 months (range 4 - 372 months). Twenty
patients had more than one detoxification
episode during the period of review.
Lofexidine was administered to achieve maximum
dosage (2.4mg) within 24 - 48 hours depending
on blood pressure response. Adjunctive medicine
was also allowable (for insomnia, pain etc).
Detoxification was considered to have been
completed if this was confirmed in the notes or 
if the patient still remained in the unit by day 14.
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Results showed that 81 patients (37.9%) remained
in treatment by day 8 and 52 (24.3%) were
considered to have completed detoxification.
Reasons for non-completion included failure of
lofexidine to adequately control the withdrawal
symptoms, psychosocial problems, or expulsion
from the programme due to breaches of the
treatment protocol (use of prohibited drugs 
or alcohol).
Blood pressure was recorded for the first 5 
days of treatment. In general, hypotension, 
when present, occurred early in treatment and
generally began to return to normal by the fourth
day. Of 144 instances of hypotension recorded,
only 23 resulted in a withholding or reduction of
the dose. The remainder resolved spontaneously
on continuing medication. Other adverse events
were not recorded routinely but where they were,
they consisted most commonly of dizziness,
drowsiness, lethargy, nausea and vomiting. 
Although the data represent a retrospective
review they are still useful in highlighting the
practical issues involved in the use of lofexidine.
They confirm that lofexidine can be used safely,
even at maximum doses. The authors argue 
that the low “completion rates” may reflect the
definition of completion of treatment used – they
suggest that many of those who had left the unit
before day 14 might have actually achieved
successful detoxification.
Finally, the practical issues of use of lofexidine 
at primary care level was discussed by 3 GPs in 
a published article (Smith et al, 1998). This report
highlighted the need to ensure that lofexidine 
is used as part of an overall treatment plan
(including counselling, self-help groups as 
well as other pharmacotherapy modalities 
such as naltrexone), in order to ensure 
long-term abstinence.
5.4.2 Ireland
Lofexidine is currently not authorised for use in
the management of opiate withdrawal in Ireland,
although an application is pending (Roberts,
personal communication). Because it is not
authorised, it has not been used in primary 
care (Delargy, personal communication) but 
it has been used by some inpatient units and
outpatient clinics on a named-patient basis. 
The following information has been received
from two treatment units in the Dublin area. 
Darndale Clinic
This is a health board out-patient treatment
centre with full time on-site nurse, pharmacist
and counsellor. It also has the services of 
doctors on a sessional basis.
A pilot project evaluating the usefulness 
of lofexidine in the management of opiate
withdrawal was begun in this centre in December
2000 (Dowdall, personal communication). Clients
were selected as suitable for Lofexidine 
by counsellors involved. They were primarily
heroin smokers or users with a relatively small
heroin habit (1 to 2Q’s per day) with a desire 
to become drug free. Also included were those 
on an existing methadone programme who 
had reduced down to low doses (less than 
20 mls) and wished to become drug free.
A total of 98 addicts participated in this project
between December 2000 and December 2002
and detailed information on these has been
made available. 
Lofexidine was prescribed using a 10 day regime
as laid down in the SPC from the manufacturer.
Symptomatic medications were also prescribed
on “as required” basis. Successful detoxifixation
was achieved if the patient’s urine was free of
opiates at the end of the programme. Lofexidine
was administered in conjunction with full medical
and counselling support and patients were seen
on a daily basis (including weekends). Participants
were usually helped by a non-drug using support
person. The patient’s GP was informed of the
programme. After successful detoxification
patients were offered Naltrexone therapy.
Counselling was available during the follow-up
period with emphasis on relapse prevention.
Links were established with rehabilitation 
services (inpatient and outpatient) in an 
attempt at relapse prevention. 
For the purpose of analysing results, patients
were subdivided into the following groups.
1. Heroin smokers (only)
2. Those on methadone programmes, either 
(a) completely stable – no heroin use in 
6 months or 
(b) continuing to dabble with heroin
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3. Those users with a more complex history 
(i.e. poly-substance users, a history of IV
heroin abuse etc.)
The overall success rate for patient attempts 
was 38% (37/98 attempts). The success rates 
for the separate groups were:
1. stable on methadone 80% (8/10)
maintenance with no 
additional heroin use
2. pure heroin smokers 39% (13/33)
3. mixed use (including 34% (14/41)
intra-venous use and 
polysubstance use)
4. unstable on methadone 14% (2/14)
programme
The data were also examined to determine the
number of patients that successfully completed
detoxification. These results differed from those
based on the number of successful attempts (above)
because some patients tried more than once.
The 98 attempts comprised 84 patients because:
 8 patients tried twice and, of these, 4 were
successful on the second attempt
 2 people tried 3 times and, of these, 1 was
successful on the third attempt and 1 was
successful first time, relapsed and failed on
the second attempt before succeeding again
on the third attempt. This patient accounted
for 2 of the 37 successes.
On this basis the success rate for patients was
43% (36/84). Serious problems with hypotension
were not reported.
Follow-up information was available for 34 of the
36 successful patients. Of these, 26 reported that
they were not using opiates and 8 had relapsed.
Of the relapsed patients, 5 chose a methadone
programme and 2 were planning repeat
lofexidine detoxification attempts. 
Dr. Dowdall has commented that the lofexidine
programme offers patients an important choice 
in treatment options. The only other outpatient
detoxification option hitherto available was a
gradual methadone dose reduction. This type 
of detoxification option has a tendency to 
lead onto methadone maintenance. 
Lofexidine is not suitable for all opiate users
wishing to undergo managed withdrawal.
Exclusion criteria include pregnancy or
underlying cardiac or renal dysfunction 
and users with serious co-existing psychiatric
morbidity. In addition, a history of polydrug 
use or high levels of alcohol consumption make
successful detoxification less likely. It was felt 
that the best indicator of success was the
patient’s motivation to become drug-free.
In summary, lofexidine has been safe to use in
this programme with only 3/98 patients (all slim
females) displaying mild signs or symptoms of
hypotension, which resolved with either omission
of a dose or a reduction in the daily dose of
lofexidine.
Fortune House/Trinity Court (outpatient
clinics)/Cuan Dara (inpatient unit)
Dr. Eamon Keenan, consultant psychiatrist, has
provided information on his experience of using
lofexidine, both at inpatient and outpatient level.
(Keenan, personal communication). Lofexidine is
used as a 10-day programme using a maximum
dosage of 2.2mg/day. Lesser doses may be
needed as an inpatient. All doses are dispensed
by the clinic pharmacy. Successful detoxification
is defined as the patient reaching day 10 of
treatment with negative urinalysis. 
In general, lofexidine has been found to be
suitable mainly for younger users with a short
history of opiate dependence. It is less effective
in those who have a long established use or a
high dosage requirement of opiates. It may also
play a role as adjunctive therapy at the end 
of reducing doses of methadone, used for
detoxification.
Lofexidine is not used in pregnant women.
Hypotension has been seen with lofexidine,
which may necessitate discontinuation of
treatment. In addition, lofexidine managed
withdrawal requires intensive input from all clinic
staff, (doctor, nurse, pharmacist and counsellor)
because of its short duration. Dr. Keenan is of the
opinion that lofexidine’s place is in the outpatient
management of opiate withdrawals for patients
who are younger with less entrenched addiction.
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5.5 Summary and Conclusions
Lofexidine, an α2-adrenergic agonist has been
shown to be effective in reducing the large
adrenergic component of opioid withdrawal.
Although few clinical studies, involving small
numbers of patients and using diverse treatment
regimens, have been published, the results
suggest that lofexidine is at least as good as
reducing doses of methadone and clonidine and
causes less hypotension than clonidine. In studies
where lofexidine was compared with methadone,
it appeared that the symptoms of withdrawal
occurred earlier with lofexidine and reached 
an earlier resolution. An escalating dose regimen
(to a maximum of 2.2mg/day by day 3 or 4),
administered in divided doses has been used 
in clinical practice. The duration of treatment has
ranged from 10 - 14 days including dose tapering.
It is important to note that most studies have 
also used additional medications such as
tranquillisers, +/- antispasmodics +/- anti
diarrhoeal agents to help relieve the 
symptoms of opioid withdrawal. 
Lofexidine is a non-opiate treatment which brings
about a quick detoxification. Although experts in
this area have suggested that lofexidine is more
effective for younger users or those with a brief
history of opiate use, the data from controlled
trials are not sufficient to support this. Lofexidine
has also been shown to be more effective in
those with a stable home situation but numbers
are small here. Because the detoxification
process with lofexidine is rapid (10 - 14 days) 
it requires close involvement of the entire 
drug treatment team with the patient during 
the withdrawal process and this may have
resource implications. Furthermore, most workers
recommend that lofexidine treatment is followed
by a treatment programme including opioid
antagonists and counselling to prevent relapse.
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Illicit opiate use has been a public health
problem in Ireland since the early 1980’s and
drug-related deaths are an important cause of
premature mortality. Methadone maintenance
has been available since the 1990s and is the
mainstay of treatment in Ireland. A review was
previously undertaken on the effectiveness of
buprenorphine as an intervention in the
management of opiate dependence syndrome.
The current review evaluated the effectiveness 
of lofexidine in the management of opiate
dependence. A systematic review of all available
data, retrieved from the published literature, was
undertaken. Contact was made with experts in
Ireland who have clinical experience in the use 
of lofexidine in order to evaluate the practical
issues associated with their usage.
The results of the review may be summarised 
as follows:
1. Lofexidine has been evaluated for use in
managed opioid withdrawal (detoxification)
and has been seen to be at least as effective
as clonidine and reducing doses of
methadone, the currently used treatment
modalities. It was not possible to identify 
the most appropriate treatment regimen
(either in terms of dosage or treatment
duration) because of the limited number 
of studies identified and the heterogeneity 
of the data contained therein.
2. Use of lofexidine was not associated with
significant levels of hypotension, making it a
suitable treatment for use in the outpatient
setting.
3. It is not possible to make definitive statements
about use of lofexidine in specific subgroups,
but it has been suggested that response 
is better in younger opiate users or those 
with a shorter history of abuse. It is not
recommended for use during pregnancy 
and there is no information on its use in 
this subgroup.
4. Reports from usage in clinical practice suggest
that managed withdrawal using lofexidine
requires the close involvement of all members
of the drug treatment team with the patient
during treatment and that lofexidine
detoxification should be followed by further
treatment (such as opioid antagonist therapy)
and counselling to prevent relapse.
In conclusion, this review suggests that lofexidine
may be regarded as a useful additional treatment
option in the overall management of opiate
dependence. 
Summary and Conclusions
Chapter 6
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(1) Background Data on 
Clinic Protocol
Please give a brief description of the clinic 
set-up in terms of doctor/ pharmacist/ nurse/
counsellor input and whether patients have
dispensing and supervised administration of
withdrawal/ substitution drug at clinic or local
pharmacy level (irrespective of drug type)
How often are patients seen (assuming a daily
dosage regimen for all medications)? 
(tick for yes as appropriate)
Daily 
Alternate days 
Weekly 
> weekly 
Do patients get each dose on a daily basis
(either at clinic or local pharmacy)?
Yes/No (please delete as appropriate)
If no, do they get majority of doses under
daily supervision with “take-aways” according
to their compliance?
Yes/No (please delete as appropriate)
If no, how are their supplies of medication
controlled? (please specify)
How often are urines taken for analysis in
induction phase? (tick for yes as appropriate)
Daily 
2-3 per week 
Weekly 
> weekly 
How often are urines taken for analysis in
maintenance phase? (tick for yes as appropriate)
Daily 
2-3 per week 
Weekly 
> weekly 
(2) Practical Aspects of 
Lofexidine Usage
1. Do you use/have you used lofexidine in 
the management of opiate dependence?
Yes/No (delete as appropriate)
2. If yes to 1. do you use it for 
(tick for yes as appropriate)
a. treatment of withdrawal only? 
b. other uses? (please specify) 
3. Do you use other therapies for the
management of opiate withdrawal? 
(delete as appropriate)
a. clonidine Yes/No
b. methadone Yes/No
c. naltrexone Yes/No
d. naloxone Yes/No
e. dihydrocodeine Yes/No
Questions on the Use of Lofexidine in the
Pharmacological Management of Opiate Dependence
Appendix I
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f. other opiate substance (please specify) 
g. other drug (please specify)
4. If lofexidine is used for treatment of
withdrawal, what dosage regimen is used?
(please specify) 
5. How does lofexidine compare with other drug
regimens in the treatment of withdrawal? (tick
for yes as appropriate and assume optimal
dosage of lofexidine)
a. Equal to comparator regimen(s)
(please specify) 
b. More efficacious 
c. Less efficacious 
d. Less side effects 
e. Less withdrawal symptoms 
f. Other comment (please specify) 
6. Do you notice a linear dose-response for
lofexidine?
Yes/No (delete as appropriate)
Any additional comments on this issue 
7. Is lofexidine suitable for the following patient
groups? (tick for yes as appropriate)
a. Males 
b. Females 
c. Pregnant females 
d. Patients on anti-HIV medication 
e. Pregnant females on anti-HIV 
medication 
f. Patients with liver disease 
g. Patients currently on methadone
maintenance 
h. Patients with high opiate 
requirements 
i. Patients with longstanding 
dependence 
j. Patients with active/history of 
depression 
k. Patients with psychosocial problems 
l. Patients requiring treatment with
psychotropics (please specify drugs) 
Any other group (please specify)
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8. If lofexidine is not suitable for specific groups
in question 7, please state the reasons
9. In your opinion, does lofexidine have an
advantage in the management of withdrawal
over other treatment modalities in any 
of the subgroups outlined in question 7? 
Yes/No (delete as appropriate)
Please give reasons for your answer
(3) Practical/Clinical Issues with
Lofexidine Usage
10.What are the common side effects
encountered with lofexidine in the 
treatment of withdrawal?
11.Is hypotension a commonly occurring
problem?
Yes/No (delete as appropriate)
12.Are the side-effects transient/present 
for duration of treatment
Yes/No (delete as appropriate)
Would the occurrence of side-effects result 
in the discontinuation of use of lofexidine 
and change to another treatment?
Yes/No (delete as appropriate) 
If yes, state circumstances
13.Does the use of lofexidine necessitate 
a change in the way opiate withdrawal 
is managed at clinic level, with respect 
to other treatment modalities (in terms 
of administration/medical supervision/other) 
Yes/No (delete as appropriate)
Please give reasons for your answer 
14.Is the issue of lofexidine-drug interactions
(either with co-prescribed drugs/illicit drugs) 
a problem in clinical practice? (see also next
question) 
Yes/No (delete as appropriate)
If yes, would you describe the problem as
major/moderate/minor? (delete as appropriate)
Please give reasons for your answer 
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15.If Yes to 14, which drugs are most
problematic? (please number 1 – 7 
with 1 being the most problematic)
a. Benzodiazepines (please record specific
drug(s) if difference between the class) 
b. SSRIs/SRIs (please record specific drug(s) 
if difference between the class) 
c. Other anti-depressants (please specify) 
d. Neuroleptics (please specify) 
e. Other opiates (please specify) 
f. Alcohol (please specify details of amount 
if appropriate) 
g. Other drugs (please specify) 
16.Are there factors which contra-indicate the use
of lofexidine in the management of withdrawal
in clinical practice (medical/practical/other) 
Yes/No (delete as appropriate)
Please outline the factors if present 
17.Are there any other particular problems with
use of lofexidine in practice (i.e. not seen 
with the other medications used)?
Yes/No (delete as appropriate) 
Please give reasons for your answer
30
18.How do you rate lofexidine as a treatment for
withdrawal in comparison to other treatment
modalities?
(assume optimal dosage of lofexidine)
Clonidine:
a. Treatment not used in the clinic 
b. Equal to clonidine 
c. Better than clonidine 
d. Less efficacious than clonidine 
e. Less side effects 
f. More side effects 
g. Less abuse potential 
h. More abuse potential 
i. Better than clonidine for 
some subgroups (please specify) 
Methadone:
a. Treatment not used in clinic 
b. Equal to methadone 
c. Better than methadone 
d. Less efficacious than methadone 
e. Less side effects 
f. More side effects 
g. Better than methadone for 
some subgroups (please specify) 
Naltrexone:
a. Treatment not used in the clinic 
b. Equal to naltrexone 
c. Better than naltrexone 
d. Less efficacious than naltrexone 
e. Less side effects 
f. More side effects 
g. Less abuse potential 
h. More abuse potential 
i. Better than naltrexone for 
some subgroups (please specify) 
Buprenorphine:
a. Treatment not used in the clinic 
b. Equal to buprenorphine 
c. Better than buprenorphine 
d. Less efficacious than buprenorphine 
e. Less side effects 
f. More side effects 
g. Less abuse potential 
h. More abuse potential 
i. Better than buprenorphine for 
some subgroups (please specify) 
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Other opiates/other treatment modalities
(please specify)
a. Equal 
b. Better 
c. less efficacious 
d. less side effects 
e. more side effects 
f. Better than                        for some
subgroups (please specify groups 
and reasons) 
19.Overall, what is your impression 
of the usefulness of lofexidine in the
management of opiate dependence? 
(4) Any additional comments you
may wish to make may be
included here.
Name of Respondent
Practice Address 
End of questionnaire. Thank you!
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